In a series of videos, our leading
oncology experts discuss EGFR-TKI treatment strategies in patients with
EGFR mutation-positive advanced non small cell lung cancer (EGFRm+
NSCLC). Watch our experts share the clinical evidence for 2nd generation
EGFR-TKI, Afatinib, and the evidence for sequential therapy in EGFRm+
NSCLC. Learn more about the real world evidence of Afatinib dose modification and
adverse event management strategies.
FEATURED VIDEOS
Care for the Skin: EGFR TKI-related
Dermatological Adverse Events
Watch A/Prof. Lee take us through the
timeline of dermatological AEs associated with EGFR-TKIs as well as the
pathophysiological mechanisms underpinning them. Learn how to distinguish
between the various cutaneous AEs and the evidence-based treatments for them.
Speaker:
Assoc Prof Lee Haur Yueh Document ID: PC-MY-101366
Promoting Ideas and Solutions, in order
to Push Improvements in pRecesion Medicine - INSPIRE aims to share the latest
updates and perspectives regarding non-small cell lung cancer. Hear from various
leading experts all over the world on the current developments in lung cancer and
its management.
FEATURED VIDEOS
Biomarker Detection in Lung Cancer
: The Pros and Cons of Multiplex Testing Part 1
Speaker:
Herbert Ho-Fung LOONG Document ID: SC-MY-00938
What is Afatinib (Giotrif®)?
Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 countries. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor mutation-positive (EGFR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]
*Afatinib is approved in more than 70 countries including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib®
*Afatinib is approved in more than 70 countries including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib®
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about Afatinib (Giotrif®)?
The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the Local Prescribing Information.
References:
[1] GIOTRIF® Summary of Product Characteristics 2018
[2] Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
[3] Wu YL et al. Lancet Oncol 2014;15(2):213–22.
[4] Park K et al. Lancet Oncol 2016;17(5):577–89.
The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the Local Prescribing Information.
References:
[1] GIOTRIF® Summary of Product Characteristics 2018
[2] Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
[3] Wu YL et al. Lancet Oncol 2014;15(2):213–22.
[4] Park K et al. Lancet Oncol 2016;17(5):577–89.